Ruti Aga's Six Years: When a Forged Prescription Weighed More Than the Banned Substance

On Thursday, the Athletics Integrity Unit (AIU) statement on Ruti Aga went live in the afternoon, Nairobi time. I read it three times, and each time my eyes stopped at the same place: a prescription written on an old pad from a clinic, by a relative, for a patient named Ruti Aga, with a diagnosis of knee pain. The clinic named on the stamp told the AIU it had never issued that prescription. The former workplace the prescriber cited confirmed she had never been on staff. And the name on the signature line, checked against the professional register, belonged to no doctor.

Six years. That is the entire remainder of a peak career.

I stayed in the office an hour longer, pulling up the footage from Tokyo 2026, the morning Aga came home cold and damp, hands raised then dropped very quickly, as if she herself could not quite believe she had just won a major marathon. Between those two images — a 25-year-old crossing the line in Tokyo and a forged medical slip submitted to an anti-doping body — lie seven years, and a lesson athletics has not finished learning.

Who Ruti Aga is

Her standing has to be established before the sanction, otherwise the story gets read as an accident that happened to a nobody.

Aga is an Ethiopian marathoner, born in 2026, now 32. She won the 2026 Tokyo Marathon, one of the six largest road races on earth, where every elite start is contested. Around that, she finished runner-up three times at World Marathon Majors events. Through the 2026–2026 window she sat inside the top ten women's road runners in the world, and in Ethiopia — where a national team place is harder to earn than an Olympic place in most countries — her name appeared in every selection conversation.

I have spent afternoons at Kasarani watching Kenyan women's squads do relay work, and there was always a small group of Ethiopian athletes standing off the track, watching, saying nothing. They come to learn how Kenyans distribute effort over the final laps. East African athletics is a small market; everyone knows everyone. In that market, Aga's name sits in the category reserved for people who race with their heads rather than their legs.

The triggering result was a half marathon in China in March, which she won. The statement does not disclose the time. That matters, and I will say it plainly: without the mark, any inference about the sporting significance of that race is speculation. No comparison to course record, to her personal best, to the standard of the field. The information is missing, and I am leaving the gap open rather than filling it with guesswork.

But one thing does not need a number. Chinese half marathons and marathons became, over the past decade, a distinct economic circuit for East African road runners: appearance fees, prize money, invitation contracts, and a schedule running from March to November. Ethiopian and Kenyan athletes fly out in groups, handled by agents, race three or four times a season, and return. It is steadier income than prize money at the majors, because it does not depend on winning.

That kind of circuit is where athletes and control systems collide most often. Dense schedules, constant travel, thin medical staffing, and a small knee injury is enough to make someone handle it themselves instead of following procedure.

A knee medication

The substance was methylprednisolone.

Many reports call it a steroid. That is wrong on classification, and wrong in the direction that makes the case look worse than it is. Methylprednisolone is a synthetic glucocorticoid — a corticosteroid used to reduce inflammation, typically injected into a joint or taken orally during flare-ups of arthritis, tendonitis, asthma. It sits in WADA class S9, prohibited in competition only, and it is a Specified Substance.

The Specified Substance category exists for a specific reason: these are substances more plausibly linked to therapeutic or inadvertent use rather than performance enhancement. The baseline sanction is therefore softer, and a Therapeutic Use Exemption is the legal, permitted route for an athlete who needs the medication for medical reasons.

This is where the case forks.

If Aga genuinely had knee pain — and I have no reason to think she invented the pain — she had a lawful path: apply for a TUE, or use the medication far enough outside competition, or simply declare it honestly when tested. Any of those three leads somewhere else entirely: no violation, or a minor one with a reduced sanction.

Instead, the record shows a prescription was created.

I have spent years writing about doping cases in East Africa, and what I have learned is that most athletes do not know what a TUE is. They know "my doctor's medicine" and "banned medicine." The gap between those two concepts is exactly where cases like this are born.

The arithmetic of the code

WADA's code contains a principle rarely discussed outside sports law: when an athlete commits multiple violations in one case, the sanctions are served consecutively, not concurrently.

Aga's ban is built from two parts. First, two years for the presence of methylprednisolone — the baseline for a Specified Substance where intent to enhance performance is not established. Second, four years for tampering during results management. Two plus four equals six.

The point a normal reading skips: the penalty for the cover-up is double the penalty for the substance. Under the code, tampering with results management is an independent, separately sanctionable violation with its own, heavier baseline. You are punished more severely for lying about having taken medication than for having taken it.

For a 32-year-old, the difference between two years and six years is not a difference in emotional pain. It is the difference between a missed appointment and a farewell. At 34, a female marathoner can still return to major racing. At 38, after six years without competition, without testing, without seeding, without invitations, the door closes in a way nobody reopens.

The ban runs from 10 September. From that date, Aga is no longer an active athlete. She is a name in a file.

The clinic that does not exist

The section I read most carefully was the evidence, because it shows what the AIU actually checked.

The prescription submitted in her defence stated that Aga was treated for a knee condition at a clinic, signed by a doctor. The AIU contacted the clinic directly. The clinic replied that the prescription was not theirs. The body checked the signatory's name against the medical register: no entry. The signatory was a family member. Asked where the prescription pad came from, that person said it was an old pad from a former workplace. The former workplace was contacted and confirmed the person had never been employed there.

Four layers of verification, four times the same result.

One methodological detail stands out: the entire chain was completed quickly, with ordinary phone calls and database checks. Which means that, in the current system, a fake medical document is close to impossible to sustain. Clinics have phone numbers, people who answer, records on file. Professional registers are public data. Former employers keep staff lists. You do not need a complex investigation to detect a forged slip; you need to make a call.

Which makes me ask whether the person who created that document understood what they were doing. On the record, the answer appears to be no — or yes, but with nobody nearby to say this will be checked within two weeks.

I once wrote about the opposite case here in Kenya: a young athlete tested out of competition, panicking, calling her manager. The manager told her to declare exactly what she had taken, including vitamins, including cold medicine. Result: no violation. The difference between the two stories is one phone call.

The Chinese circuit and the money underneath

There is an economic dimension the statement does not address but which sits right at the surface.

The March half marathon result will almost certainly be annulled, along with its prize money. For a world-class athlete, prize money at a minor race is not the main income. The main income is the appearance fee: a fixed sum paid by organisers for a name that draws spectators and local sponsors. That sum does not appear on any results sheet, is not publicly disclosed, and is not clawed back by any sanction, because it was paid in advance.

After 10 September, no organiser signs another appearance contract with an athlete serving six years.

I call this the commercial death that arrives before the competitive one. For an East African distance runner, income comes from four sources: appearance fees, prize money, shoe contracts, and major-race invitations. The sanction erases all four at once, and permanently, because the buyers of those four things are not fans. They are race organisers and sponsors, and they read AIU files before they read results.

There is a wider consequence Asian race organisers will have to price in. Races that invite East African athletes operate on an assumption: that the name invited is a clean name. When a doping file attaches to a specific race, that race absorbs reputational damage with no compensation mechanism. Invitation vetting will likely tighten — medical documentation, TUE confirmation, termination clauses on violation. It is a small change, but it raises administrative cost for an entire cohort of East African athletes, including those with nothing to do with this case.

Behind the stadium lights, women whisper what the world has not heard. One of the things they whisper is that every doping case gets socialised across the whole group.

Age 32 and age 38

At 32, Aga was in the second peak of her career curve — the phase when female marathoners typically run best. The elite window extends to roughly 35, sometimes 37 for athletes with durable foundations and few injuries. The sanction did not land as she was declining, when people could say it was about time. It landed at the point of maximum value.

Six years from 10 September puts her at roughly 38.

On paper, she can return. In practice, the probability is very low, and I want to say why in specifics rather than in feeling.

First, six years without competition means six years without in-competition testing — but also six years with no results to prove capability. No organiser invites an athlete just out of a doping ban without a mark inside the previous twelve months. It is the classic loop: to be invited you need a result, to get a result you need an invitation.

Second, the knee injury cited in the record is not the kind of injury that disappears in six years. It accumulates.

Third, and least discussed: an athlete returning from a doping ban does not only have to run fast. She has to run fast in an environment where every start comes with a test, every result is read differently, and every knock on the door is stress. Very few people carry that at 38.

I have followed a handful of long-ban returns in athletics. The ones that worked had two things in common: they were young when the ban expired — under 30 — and they had a training system strong enough to shield them from outside pressure. Aga has neither advantage.

Purely competitively, this ban does not shift the balance of women's marathoning. Ethiopia's development system is deep enough that one lost place creates almost no gap. The replacement for her position in the elite group is already there, waiting, and running faster every year. That is the signature of a deep athletics nation: an individual can lose everything while the system loses nothing.

The sentence for the cover-up

Here is the centre of the case, and where most coverage goes wrong.

Aga was banned six years for taking an anti-inflammatory and then creating a fake document. If she had only taken the medication, the baseline is two years — and for a Specified Substance with a credible medical explanation, that can fall to months or to nothing. If she had taken it and declared it honestly, the story might have been a lesson about missing TUEs, closed in three months.

The extra four years came from the slip of paper.

I understand why the rule is written that way. If tampering were not punished more heavily than the underlying violation, every athlete would try it, because expected gain exceeds expected cost. The penalty structure has tight internal logic.

But there is an asymmetry I cannot ignore. A 32-year-old can understand that a banned substance is banned. She is unlikely to understand that a prescription written by a relative counts as a separate, heavier violation. Nobody told her that before she filed. And in most East African training groups, nobody is equipped to tell her.

That is the blind spot: the system is excellent at punishing and thin at educating. The AIU runs online courses, publishes guidance, staffs a helpline. An athlete training in Iten, running 200 kilometres a week, does not read online guidance. She asks the nearest person. In this case, the nearest person was a relative.

The cost of having no one beside you

In 2026, in the World Cup media area in Russia, I met a communications officer with the Senegal national team. She told me she had been barred from the dressing room because she was a woman. I wrote a long piece about the women running that World Cup from behind the scenes. It drew 50,000 reads, ten times the standard pieces that week.

What I took from that piece was not technique. It was that every sports system has a layer of workers the system does not see, and that layer determines whether the system functions. For Aga, that layer is the person handling medical paperwork, TUEs, and cross-checking the prohibited list before every course of treatment.

In her case, that layer did not exist. Or worse: it existed in the form of a well-meaning relative with no expertise.

Gender equality in sport is not a fight with men; it is a match against prejudice. One of the most durable prejudices is that female athletes from developing nations are assumed to need less professional support, because they are used to managing alone. The price of that assumption, here, was four years.

I have no information on who advised Aga during her defence. The statement does not say. But the shape of the failure — a fictional clinic, an old pad, an unregistered signatory — carries the signature of someone who did not know how verification works. A sports lawyer would never file that. An experienced manager would never let it leave the desk.

Which is why responsibility does not stop with the athlete, and why this sanction, however correct in law, lands on the weakest link in the chain.

What this story does not say

The reading I want to stop before it spreads is: another Ethiopian doping case.

The record does not support it. This is an individual, clumsily executed case by people without expertise, detected through routine checks. There is no sign of a system, an organisation, or a programme. The clumsiness argues the opposite: an organised scheme would not leave behind a prescription that can be tested with one phone call.

Ethiopia and Kenya share a different structural problem: the number of world-class athletes far exceeds the support infrastructure. When you have hundreds of women running under 2:25 and only a handful of anti-doping law specialists, error rates rise. That is a problem of scale, not of culture.

The second correction concerns the substance. Methylprednisolone is not an anabolic steroid. It is an anti-inflammatory. Calling it a steroid invites the public to picture a completely different scenario — hormone injections for muscle — and distorts any judgement of severity. The truth of this case is: a woman with a sore knee took an anti-inflammatory, then forged paperwork to prove she had taken an anti-inflammatory.

It sounds small. It cost six years.

What will change

This case will not change marathoning. It will not slow anyone down, alter a schedule, or cost Ethiopia a medal. In six months it will be a line in the AIU database.

It may change something smaller and more concrete: how training groups in East Africa handle medical paperwork.

I have seen signs. Some camps in Iten have started pinning the prohibited list to the gym wall. Some managers now require athletes to photograph every prescription and send it before use. Some young athletes, asked what a TUE is, can answer — which ten years ago almost nobody could.

None of that makes the news. It is the only thing that prevents the next case.

For Aga, nothing is left to change. Six years are signed. She will not run Tokyo again, or Berlin, or any major race for the rest of a competitive life. The only thing still open is how we tell this story.

I choose to tell it as a story about a piece of paper.

A slip written on an old pad, by someone trying to help, for someone in pain. Had one person who knew the rules been sitting beside her that day, the slip would not exist. And Ruti Aga, at 33, would be preparing for another season.

A pitch remembers not only the goals, but the hands that help someone back to their feet. On the long road, those hands have to arrive before the stumble. After the stumble, every hand is too late.

Every transfer contract is a departure from home, and I listen from the silent side. On the silent side of this case is a 32-year-old woman who lost a career over a document she did not write. And a sport that still has not built the desk she should have been sitting at years ago, while there was still time.